Annals of clinical and laboratory science · 2026
Prognostic Markers for Early Mortality in Acute Mesenteric Ischemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Öz Medine Akkan, Mutlu Hüseyin, Yazıcı Ramiz, Bulut Bensu, Gür Ayşenur, Yatmaz Yunus, Yortanlı Mehmet, Güner Hakan, Kotanoğlu Mustafa Sırrı, Uysal Zekeriya
Аннотация
OBJECTIVE: Acute mesenteric ischemia (AMI) is a high-mortality vascular emergency caused by impaired intestinal perfusion due to embolic or thrombotic obstruction. Reliable biomarkers are needed for early diagnosis and prognostic evaluation. This study aimed to investigate the value of the lactate dehydrogenase/albumin ratio (LAR) in predicting 28-day mortality in AMI patients and to compare its prognostic performance with other inflammatory markers.
METHODS: This retrospective cohort study included 129 adult patients diagnosed with AMI by contrast-enhanced computed tomography angiography. Patients were divided into survivors and non-survivors according to 28-day outcomes. LAR, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and CRP/albumin ratio (CAR) were calculated, and prognostic factors associated with mortality were analyzed.
RESULTS: 34.1% of patients (n=44) died within 28 days. Mean age, LAR, lactate, NLR, and PLR were significantly higher in the mortality group (p<0.001). In the ROC analysis, LAR had the highest discriminatory power in predicting 28-day mortality (AUC=0.820; 95% CI: 0.758-0.883; p<0.001). The optimal threshold of 9.9 yielded 71.1% sensitivity and 90.9% specificity.
CONCLUSION: LAR is a strong prognostic marker for 28-day mortality in AMI patients and may support risk stratification and treatment management using routine laboratory parameters.
METHODS: This retrospective cohort study included 129 adult patients diagnosed with AMI by contrast-enhanced computed tomography angiography. Patients were divided into survivors and non-survivors according to 28-day outcomes. LAR, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and CRP/albumin ratio (CAR) were calculated, and prognostic factors associated with mortality were analyzed.
RESULTS: 34.1% of patients (n=44) died within 28 days. Mean age, LAR, lactate, NLR, and PLR were significantly higher in the mortality group (p<0.001). In the ROC analysis, LAR had the highest discriminatory power in predicting 28-day mortality (AUC=0.820; 95% CI: 0.758-0.883; p<0.001). The optimal threshold of 9.9 yielded 71.1% sensitivity and 90.9% specificity.
CONCLUSION: LAR is a strong prognostic marker for 28-day mortality in AMI patients and may support risk stratification and treatment management using routine laboratory parameters.